Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.

Detalles Bibliográficos
Autores principales: Lalli, Giovanna, Schott, Jonathan M, Hardy, John, De Strooper, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350893/
https://www.ncbi.nlm.nih.gov/pubmed/34338436
http://dx.doi.org/10.15252/emmm.202114781
Descripción
Sumario:On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.

Ejemplares similares